Zaltoprofen
Zaltoprofen (JAN; trade name Soleton) is a nonsteroidal anti-inflammatory drug (NSAID) used as an analgesic, antipyretic, and anti-inflammatory agent.[1] It is a selective COX-2 inhibitor and also inhibits bradykinin-induced pain responses without blocking bradykinin receptors.[2]
![]() | |
| Clinical data | |
|---|---|
| Trade names | Soleton |
| Other names | Zaxoprofen |
| Drug class | NSAID |
| Legal status | |
| Legal status |
|
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| DrugBank | |
| UNII | |
| CompTox Dashboard (EPA) | |
| ECHA InfoCard | 100.070.863 |
| Chemical and physical data | |
| Formula | C17H14O3S |
| Molar mass | 298.36 g·mol−1 |
| 3D model (JSmol) | |
| |
It was approved for use in Japan in 1993.[3]
References
- "Zaltoprofen". drugs.com.
- Hirate K, Uchida A, Ogawa Y, Arai T, Yoda K (April 2006). "Zaltoprofen, a non-steroidal anti-inflammatory drug, inhibits bradykinin-induced pain responses without blocking bradykinin receptors". Neuroscience Research. 54 (4): 288–94. doi:10.1016/j.neures.2005.12.016. PMID 16473424.
- "Zaltoprofen Launched in Japan". thepharmaletter.com. September 20, 1993.
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.
